NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Tacalyx

Tacalyx

Private
BerlinHealthcare & Life Scienceshttps://www.tacalyx.com/

Last Round

Seed

Apr 29, 2026

Total Funding Raised

$28M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Tacalyx is a biotechnology company that develops novel anticancer therapeutics targeting Tumor Associated Carbohydrate Antigens (TACAs).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

therapeutic antibodiestumor-associated carbohydrate antigensTACAoncology drug discoveryglycobiologyantibody-drug conjugatesADCbiotech drug pipelinecancer immunotherapytarget validationdrug development platformbiotech licensingglycan researchpre-clinical research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tacalyx Comps

Public and private peers based on sector, stage, and business model.

Tacalyx comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Tacalyx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedApr 29, 2026
SeedJun 11, 2024
SeedSep 25, 2019

Key People

Founding team and executive leadership

Jean Engela

CEO, Managing Director Geschäftsführer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 29, 2026

    $12M round with participation from Eurazeo and Boehringer Ingelheim.

  • Feb 16, 2026

    Grew 23% QoQ from 13 to 16 employees.

Tacalyx Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Tacalyx Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Tacalyx's valuation, stock price, and market status.

Firmographic Details

HeadquartersBerlin
Employee Range16
Year Founded2019
Last FundingApr 29, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.